Research On The Construction Of Advantages Of Pharmaceutical Business Ecosystem

The pharmaceutical industry is a sunrise industry in the world.With the development of global economic integration,the competition in the pharmaceutical industry is becoming increasingly fierce,and pharmaceutical enterprises are actively seeking ways for sustainable development.As a strategic high point,the pharmaceutical industry is closely related to the national economy and the people’s livelihood.With a large population base and an accelerating aging population in China,the urgency of the development of the pharmaceutical industry cannot be ignored.However,China’s pharmaceutical industry has problems such as dispersed layout,serious homogenization of products and weak innovation ability.For this reason,leading Chinese pharmaceutical enterprises actively build a business ecosystem advantage with themselves as the core.This study uses a combination of qualitative case study and quantitative industry analysis to draw conclusions.Firstly,an exploratory case study is carried out at the micro level to describe and analyze the process of constructing the advantages of the business ecosystem of Shanghai Pharmaceuticals Holding Co.,ltd.and Jointown Pharmaceutical Group from the perspective of three stages: strategic resource positioning,product cooperation and innovation,market chain operation and distribution,and information technology habitat.First,it is concluded that the business ecosystem architectures represented by Shanghai Pharmaceuticals Holding Co.,ltd.and Jointown Pharmaceutical Group are "closed integrated type" and "open coupled type" respectively.Second,it summarizes the process of constructing advantages of the business ecosystem represented by Shanghai Pharmaceuticals Holding Co.,ltd.and Jointown Pharmaceutical Group in the stage of "seeking survival,seeking development and seeking the future",and identifies the model of the advantages construction process and the evolutionary path.The three-stage competitive advantages are respectively "market scale advantage","key products and platform advantage" and "ecological integration advantage",and the evolutionary paths are "sinking into the market" and "breaking through the market" respectively.Third,it analyzes the deep-seated reasons for the construction of advantages of the business ecosystem of the two types of pharmaceutical enterprises,and summarizes two types of trust mechanism models,namely "capability aggregation trust mechanism" and "relationship diffusion trust mechanism".Secondly,empirical research is carried out at the industry level,using the ecological index system of resources,technology,market and habitat to empirically analyze the differences in the niche suitability level of Chinese pharmaceutical business ecosystem,to verify whether the business ecological environment where the typical cases are located has a higher core competitive advantage,to draw directions for improvement,and to strengthen the reliability of the conclusions of the case study.First,there is more room for improvement in the niche suitability of China’s pharmaceutical business ecosystem,with only eight provinces and cities higher than the national average,and the niche suitability of the provinces and cities where the typical case headquarters is located ranks second and seventh,respectively,with a relatively high level of suitability.Second,the market niche suitability level of China’s pharmaceutical business ecosystem is relatively high.Third,the level of niche suitability of each province and city is distributed in a gradient,and the third gradient has room for breakthrough.Fourth,each province and city has its own advantages in different ecological elements.Fifth,the competitive advantages in terms of resources,technology,market and habitat brought by the business ecosystem constructed by pharmaceutical enterprises provide the direction of improvement for pharmaceutical enterprises.Overall,while the Chinese pharmaceutical business ecosystem is currently building certain competitive advantages,the level of innovation needs to be further improved.The business development is mainly focused on generic drugs,with insufficient investment in R&D of innovative drugs and insufficient transformation of results.In the future,it is necessary to master core technologies and promote the improvement of R&D capabilities of high-end generic drugs and innovative drugs,etc.The above studies enrich the research on the competitive advantages of the business ecosystem,with a view to providing theoretical reference and practical reference for Chinese pharmaceutical enterprises to build the business ecosystem and enhance their core competitive advantages,as well as providing relevant policy suggestions for the sustainable development of the Chinese pharmaceutical industry.